ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA Grants Bold Therapeutics' BOLD-100 an Orphan Drug Designation (ODD) in the Treatment of Gastric Cancer
May 12, 2021Bold Therapeutics, a clinical-stage biopharmaceutical company, announced that the U.S. Food & Drug Administration (FDA) has granted BOLD-100 an Orphan Drug Designation (ODD) in the treatment of gastric (stomach) cancer. -
BOLD-100 significantly outperforms remdesivir head-to-head in SARS-CoV-2 model
August 20, 2020Bold Therapeutics, a clinical-stage biopharmaceutical company, recently generated additional data supporting rapid clinical development of BOLD-100 as a novel antiviral.
Pharma Sources Insight January 2025
